Q2 2024 Earnings Call Transcript November 12, 2024 Operator: Good day and thank you for standing by. Welcome to the Roivant ...

Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

To evaluate the influence of environmental factors and prematurity relating to juvenile dermatomyositis (JDM), its course and refractoriness to treatment. Maternal exposure to occupational pollutants ...

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...

The drug – called brepocitinib – is the centrepiece of the new biotech's R&D pipeline and is already a pair of pivotal trials in patients with dermatomyositis and systemic lupus erythematosus ...

Batoclimab data coming next year in MG, CIDP and TED and brepocitinib in dermatomyositis top line data coming in ... We really only had one additional subject in each dose arm of the treatment failure ...

Two other patients with dermatomyositis and diffuse cutaneous systemic sclerosis ... enhancement and hypokinesia detected by cardiac MRI was markedly reduced after treatment with corticosteroids and ...

The relationship between Anthony Jennings and Jam Villanueva once again reached the rumor mills, after the latter alluded to ...

Treatment with CNTY-101 continued to be safe and generally ... Idiopathic inflammatory myopathies (IIM) include a heterogenous group of rare disorders including dermatomyositis and polymyositis in ...

Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis ... delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and ...